ALBUTEIN (albumin human)
PLASMA PROTEINS · HYPOALBUMINEMIA ·+4
GRIFOLS
Drug class
Plasma Proteins
Therapeutic plasma proteins, or plasma-derived medicinal products, are biological therapeutics isolated and purified from human blood plasma. Read more about Plasma Proteins
29 drugs in this class 8 manufacturers
Drugs in Plasma Proteins
ALBUTEIN (albumin human)
PLASMA PROTEINS · HYPOALBUMINEMIA ·+4
GRIFOLS
ALBUKED-25 (albumin human)
PLASMA PROTEINS · HYPOALBUMINEMIA ·+4
Kedrion Biopharma
ALBUKED-5 (albumin human)
PLASMA PROTEINS · HYPOALBUMINEMIA ·+4
Kedrion Biopharma
ALBUMIN, HUMAN 25 % (albumin human)
PLASMA PROTEINS · HYPOALBUMINEMIA ·+4
GRIFOLS
KEDBUMIN (albumin human)
PLASMA PROTEINS · HYPOALBUMINEMIA ·+4
Kedrion Biopharma
ALBURX (albumin human)
PLASMA PROTEINS · HYPOALBUMINEMIA ·+4
CSL Behring
ALBURX (albumin human)
PLASMA PROTEINS · HYPOALBUMINEMIA ·+4
CSL Behring
ALBUTEIN (albumin human)
PLASMA PROTEINS · HYPOALBUMINEMIA ·+4
GRIFOLS
Filter & compare in the drug finder →
Opens the drug finder with Plasma Proteins preselected. Add indication or manufacturer filters there.
Therapeutic plasma proteins, or plasma-derived medicinal products, are biological therapeutics isolated and purified from human blood plasma.
Rather than acting through a single pathway, these therapies replace congenital or acquired deficiencies of vital endogenous proteins, restore oncotic pressure, or provide passive immunologic protection.
Key agents include coagulation factors such as factors VIII and IX, immunoglobulins, human albumin, and protease inhibitors like alpha-1 antitrypsin and C1-esterase inhibitor.
Clinically, they are indicated to manage life-threatening bleeding disorders, primary and secondary immunodeficiencies, autoimmune conditions, hypovolemia or shock, and genetic enzyme deficiencies.
-
nih.gov
Therapeutic plasma proteins, or plasma-derived medicinal products, are biological therapeutics isolated and purified from human blood plasma
-
nih.gov
Therapeutic plasma proteins, or plasma-derived medicinal products, are biological therapeutics isolated and purified from human blood plasma Rather than acting through a single pathway, these therapies replace congenital or acquired deficiencies of vital endogenous proteins, restore oncotic pressure, or provide passive immunologic protection Key agents include coagulation factors such as factors VIII and IX, immunoglobulins, human albumin, and protease inhibitors like alpha-1 antitrypsin and C1-...
-
fda.gov
Rather than acting through a single pathway, these therapies replace congenital or acquired deficiencies of vital endogenous proteins, restore oncotic pressure, or provide passive immunologic protection
-
nih.gov
Rather than acting through a single pathway, these therapies replace congenital or acquired deficiencies of vital endogenous proteins, restore oncotic pressure, or provide passive immunologic protection
-
amegroups.org
Key agents include coagulation factors such as factors VIII and IX, immunoglobulins, human albumin, and protease inhibitors like alpha-1 antitrypsin and C1-esterase inhibitor
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.